Cargando…

Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus

INTRODUCTION: In rheumatoid arthritis (RA) patients receiving immunosuppressive treatments, vaccination against Streptococcus pneumoniae is recommended. The objective of the study was to evaluate the effects of tacrolimus (TAC) on immune response following administration of a 23-valent pneumococcal...

Descripción completa

Detalles Bibliográficos
Autores principales: Migita, Kiyoshi, Akeda, Yukihiro, Akazawa, Manabu, Tohma, Shigeto, Hirano, Fuminori, Ideguchi, Haruko, Matsumura, Ryutaro, Suematsu, Eiichi, Miyamura, Tomoya, Mori, Shunsuke, Fukui, Takahiro, Izumi, Yasumori, Iwanaga, Nozomi, Tsutani, Hiroshi, Saisyo, Kouichirou, Yamanaka, Takao, Ohshima, Shiro, Sugiyama, Takao, Kawabe, Yojiro, Katayama, Masao, Suenaga, Yasuo, Okamoto, Akira, Ohshima, Hisaji, Okada, Yasumasa, Ichikawa, Kenji, Yoshizawa, Shigeru, Kawakami, Kenji, Matsui, Toshihiro, Furukawa, Hiroshi, Oishi, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481124/
https://www.ncbi.nlm.nih.gov/pubmed/26036592
http://dx.doi.org/10.1186/s13075-015-0662-x
_version_ 1782378245985927168
author Migita, Kiyoshi
Akeda, Yukihiro
Akazawa, Manabu
Tohma, Shigeto
Hirano, Fuminori
Ideguchi, Haruko
Matsumura, Ryutaro
Suematsu, Eiichi
Miyamura, Tomoya
Mori, Shunsuke
Fukui, Takahiro
Izumi, Yasumori
Iwanaga, Nozomi
Tsutani, Hiroshi
Saisyo, Kouichirou
Yamanaka, Takao
Ohshima, Shiro
Sugiyama, Takao
Kawabe, Yojiro
Katayama, Masao
Suenaga, Yasuo
Okamoto, Akira
Ohshima, Hisaji
Okada, Yasumasa
Ichikawa, Kenji
Yoshizawa, Shigeru
Kawakami, Kenji
Matsui, Toshihiro
Furukawa, Hiroshi
Oishi, Kazunori
author_facet Migita, Kiyoshi
Akeda, Yukihiro
Akazawa, Manabu
Tohma, Shigeto
Hirano, Fuminori
Ideguchi, Haruko
Matsumura, Ryutaro
Suematsu, Eiichi
Miyamura, Tomoya
Mori, Shunsuke
Fukui, Takahiro
Izumi, Yasumori
Iwanaga, Nozomi
Tsutani, Hiroshi
Saisyo, Kouichirou
Yamanaka, Takao
Ohshima, Shiro
Sugiyama, Takao
Kawabe, Yojiro
Katayama, Masao
Suenaga, Yasuo
Okamoto, Akira
Ohshima, Hisaji
Okada, Yasumasa
Ichikawa, Kenji
Yoshizawa, Shigeru
Kawakami, Kenji
Matsui, Toshihiro
Furukawa, Hiroshi
Oishi, Kazunori
author_sort Migita, Kiyoshi
collection PubMed
description INTRODUCTION: In rheumatoid arthritis (RA) patients receiving immunosuppressive treatments, vaccination against Streptococcus pneumoniae is recommended. The objective of the study was to evaluate the effects of tacrolimus (TAC) on immune response following administration of a 23-valent pneumococcal polysaccharide vaccine (PPSV23) in patients with established RA. METHODS: Patients with RA (n = 133) were vaccinated with PPSV23. Patients were classified into TAC (n = 29), methotrexate (MTX) (n = 55), control (n = 35), and TAC/MTX (n = 14) treatment groups. We measured the concentrations of pneumococcal serotypes 6B and 23F by using an enzyme-linked immunosorbent assay and determined antibody functionality by using a multiplexed opsonophagocytic killing assay, reported as the opsonization index (OI), before and 4 to 6 weeks after vaccination. A positive antibody response was defined as at least a twofold increase in the IgG concentration or as at least a 10-fold increase in the OI. RESULTS: IgG concentrations and OIs were significantly increased in all treatment groups after PPSV23 vaccination. The TAC treatment group appears to respond in a manner similar to that of the RA control group in terms of 6B and 23F serotype concentration and function. In contrast, the MTX group had the lowest immune response. Patients who received a combination of TAC and MTX (TAC/MTX) also had a diminished immune response compared with those who received TAC alone. CONCLUSIONS: TAC monotherapy does not appear to impair PPSV23 immunogenicity in patients with RA, whereas antibody production and function may be reduced when TAC is used with MTX. Thus, PPSV23 administration during ongoing TAC treatment should be encouraged for infection-prone TAC-treated patients with rheumatic diseases. TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry: UMIN000009566. Registered 12 December 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0662-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4481124
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44811242015-06-27 Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus Migita, Kiyoshi Akeda, Yukihiro Akazawa, Manabu Tohma, Shigeto Hirano, Fuminori Ideguchi, Haruko Matsumura, Ryutaro Suematsu, Eiichi Miyamura, Tomoya Mori, Shunsuke Fukui, Takahiro Izumi, Yasumori Iwanaga, Nozomi Tsutani, Hiroshi Saisyo, Kouichirou Yamanaka, Takao Ohshima, Shiro Sugiyama, Takao Kawabe, Yojiro Katayama, Masao Suenaga, Yasuo Okamoto, Akira Ohshima, Hisaji Okada, Yasumasa Ichikawa, Kenji Yoshizawa, Shigeru Kawakami, Kenji Matsui, Toshihiro Furukawa, Hiroshi Oishi, Kazunori Arthritis Res Ther Research Article INTRODUCTION: In rheumatoid arthritis (RA) patients receiving immunosuppressive treatments, vaccination against Streptococcus pneumoniae is recommended. The objective of the study was to evaluate the effects of tacrolimus (TAC) on immune response following administration of a 23-valent pneumococcal polysaccharide vaccine (PPSV23) in patients with established RA. METHODS: Patients with RA (n = 133) were vaccinated with PPSV23. Patients were classified into TAC (n = 29), methotrexate (MTX) (n = 55), control (n = 35), and TAC/MTX (n = 14) treatment groups. We measured the concentrations of pneumococcal serotypes 6B and 23F by using an enzyme-linked immunosorbent assay and determined antibody functionality by using a multiplexed opsonophagocytic killing assay, reported as the opsonization index (OI), before and 4 to 6 weeks after vaccination. A positive antibody response was defined as at least a twofold increase in the IgG concentration or as at least a 10-fold increase in the OI. RESULTS: IgG concentrations and OIs were significantly increased in all treatment groups after PPSV23 vaccination. The TAC treatment group appears to respond in a manner similar to that of the RA control group in terms of 6B and 23F serotype concentration and function. In contrast, the MTX group had the lowest immune response. Patients who received a combination of TAC and MTX (TAC/MTX) also had a diminished immune response compared with those who received TAC alone. CONCLUSIONS: TAC monotherapy does not appear to impair PPSV23 immunogenicity in patients with RA, whereas antibody production and function may be reduced when TAC is used with MTX. Thus, PPSV23 administration during ongoing TAC treatment should be encouraged for infection-prone TAC-treated patients with rheumatic diseases. TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry: UMIN000009566. Registered 12 December 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0662-x) contains supplementary material, which is available to authorized users. BioMed Central 2015-06-03 2015 /pmc/articles/PMC4481124/ /pubmed/26036592 http://dx.doi.org/10.1186/s13075-015-0662-x Text en © Migita et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Migita, Kiyoshi
Akeda, Yukihiro
Akazawa, Manabu
Tohma, Shigeto
Hirano, Fuminori
Ideguchi, Haruko
Matsumura, Ryutaro
Suematsu, Eiichi
Miyamura, Tomoya
Mori, Shunsuke
Fukui, Takahiro
Izumi, Yasumori
Iwanaga, Nozomi
Tsutani, Hiroshi
Saisyo, Kouichirou
Yamanaka, Takao
Ohshima, Shiro
Sugiyama, Takao
Kawabe, Yojiro
Katayama, Masao
Suenaga, Yasuo
Okamoto, Akira
Ohshima, Hisaji
Okada, Yasumasa
Ichikawa, Kenji
Yoshizawa, Shigeru
Kawakami, Kenji
Matsui, Toshihiro
Furukawa, Hiroshi
Oishi, Kazunori
Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
title Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
title_full Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
title_fullStr Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
title_full_unstemmed Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
title_short Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
title_sort pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481124/
https://www.ncbi.nlm.nih.gov/pubmed/26036592
http://dx.doi.org/10.1186/s13075-015-0662-x
work_keys_str_mv AT migitakiyoshi pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT akedayukihiro pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT akazawamanabu pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT tohmashigeto pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT hiranofuminori pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT ideguchiharuko pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT matsumuraryutaro pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT suematsueiichi pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT miyamuratomoya pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT morishunsuke pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT fukuitakahiro pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT izumiyasumori pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT iwanaganozomi pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT tsutanihiroshi pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT saisyokouichirou pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT yamanakatakao pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT ohshimashiro pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT sugiyamatakao pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT kawabeyojiro pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT katayamamasao pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT suenagayasuo pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT okamotoakira pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT ohshimahisaji pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT okadayasumasa pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT ichikawakenji pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT yoshizawashigeru pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT kawakamikenji pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT matsuitoshihiro pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT furukawahiroshi pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus
AT oishikazunori pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus